読み込み中
NASDAQHealthcareDrug Manufacturers - General
最新データ
$12.04
+$0.05 · +0.42%
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
通常取引
$12.04
+$0.05 · +0.42%
日中の時刻はETです。市場データは遅延する場合があります。
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
日中レンジ
現在 $12.04
52週レンジ
現在 $12.04
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
48
適正価値
センチメント
52
まちまち
リスク
43
やや高いリスク
モメンタム
40
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
日中レンジ
現在 $12.04
52週レンジ
現在 $12.04
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.14億 USD | 2.29億 USD | 3.07億 USD | 3.69億 USD | 5.83億 USD |
| 売上原価 | 9277.8万 USD | 1.47億 USD | 1.41億 USD | 1.27億 USD | 1.21億 USD |
| 粗利益 | 1.21億 USD | 8138.2万 USD | 1.66億 USD | 2.42億 USD | 4.62億 USD |
| 研究開発 | 1980.6万 USD | 2086.9万 USD | 2221.9万 USD | 3041.1万 USD | 2930.7万 USD |
| 販売・一般管理 | 1.15億 USD | 1.52億 USD | 2億 USD | 3.04億 USD | 4.08億 USD |
| 営業費用 | 1.35億 USD | 1.73億 USD | 2.22億 USD | 3.48億 USD | 4.51億 USD |
| 受取利息 | 1085.3万 USD | 1340.3万 USD | 1186.3万 USD | 281.9万 USD | 122万 USD |
| 支払利息 | 7000 USD | 7000 USD | 8000 USD | 1.5万 USD | 12.9万 USD |
| 減価償却費と償却費 | 302.8万 USD | 291.5万 USD | 296.5万 USD | 309.6万 USD | 285.7万 USD |
| 営業利益 | −1394.1万 USD | −9179.7万 USD | −5661.6万 USD | −1.06億 USD | 1050.2万 USD |
| 純利益 | −3879.8万 USD | −8218.3万 USD | −5911.2万 USD | −1.06億 USD | 772.9万 USD |
会社概要が更新されました 2026年10月9日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$2.17
下落余地（81.98%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
